Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation
Completed · Not applicable · Has a placebo group
Conditions studied: Abortion, Dilation and Evacuation, Hemorrhage, Blood Loss
In brief
Currently, there is very little research to identify ways to decrease blood loss during D\&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D\&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.
Key facts
- Study ID
- NCT02083809
- Run by
- University of Hawaii
- People needed
- 166
- Starts
- 2014-10-01
- Expected to finish
- 2018-02-01
- Last updated by the study team
- 2020-11-27
Who can join
Age: 14 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Requesting pregnancy termination
- Intrauterine pregnancy at 18- to 24-weeks gestation
- Gestational-age to be confirmed by ultrasound
- Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
- Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures
You may not qualify if…
- Ultrasound findings suggestive of placenta accreta
- Patients requiring preoperative misoprostol
Where it is running
- University of Hawaii — Honolulu, Hawaii, United States
- University of Washington — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.